Compare
Amgen vs Arrowhead Pharmaceuticals (AMGN vs ARWR)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Arrowhead Pharmaceuticals (ARWR) +44.3%; so far this year the figures are +40.7% and -12.4%.
Amgen is the larger company by market value, about 30.3 times the size of Arrowhead Pharmaceuticals.
Revenue grew +8.2% at AMGN and +16.8% at ARWR over the last year.
AMGN yields 2.16%. ARWR pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | ARWR | |
|---|---|---|
| Price | $460.42 | $58.16 |
| 1-day | +0.03% | +1.22% |
| YTD | +40.67% | -12.40% |
| 1 year | +43.94% | +44.28% |
| 3 years | +76.51% | +125.51% |
| Market cap | $249.1B | $8.2B |
| P/E | 26.7 | — |
| P/S | 6.40 | 12.27 |
| P/B | 17.35 | 17.65 |
| Revenue growth | +8.20% | +16.80% |
| EPS growth | +33.30% | — |
| Gross margin % | 70.9 | — |
| Net margin % | 24.1 | -47.8 |
| ROE % | 65.4 | -68.7 |
| Debt / equity | 3.76 | 0.00 |
| FCF yield % | 3.8 | -0.9 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 1.60 |
| RSI (14) | 60.5 | 39.6 |
| Technical rating |